Revisiting the ALA/N (a-Lipoic Acid/Low-Dose Naltrexone) Protocol for People With Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New Cases

The authors, in a previous article, described the long-term survival of a man with pancreatic cancer and metastases to the liver, treated with intravenous alpha-lipoic acid and oral low-dose naltrexone…

Continue ReadingRevisiting the ALA/N (a-Lipoic Acid/Low-Dose Naltrexone) Protocol for People With Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New Cases

The Long-term Survival of a Patient With Pancreatic Cancer With Metastases to the Liver After Treatment With the Intravenous a – Lipoic Acid/Low-Dose Naltrexone Protocol

The authors describe the long-term survival of a patient with pancreatic cancer without any toxic adverse effects. The treatment regimen includes the intravenous -lipoic acid and low-dose naltrexone (ALA-N) protocol…

Continue ReadingThe Long-term Survival of a Patient With Pancreatic Cancer With Metastases to the Liver After Treatment With the Intravenous a – Lipoic Acid/Low-Dose Naltrexone Protocol

Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease

The objective of this study was to evaluate the safety, tolerability, and preliminary efficacy of intravenous glutathione in Parkinson's disease (PD) patients. This was a randomized, placebo-controlled, double-blind, pilot trial…

Continue ReadingRandomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease